“When we compare it with other skin diseases, it is one of the itchiest of all, it highly impacts the quality-of-life and physical, emotional, and psychological well-being,” Prof. Franz Legat (Medical University Graz, Austria) explained about PN [1].
Prof. Legat presented the results of the phase 3b durability study on nemolizumab (NCT05052983), the first FDA-approved IL-31 receptor alpha antagonist. Eligible participants all had a clinical response at week 52 of the ongoing OLYMPIA-LTE trial (NCT04204616) defined by an Investigator Global Assessment (IGA) 0/1 and a ≥4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS). Matching the entry requirements, 58.8% of participants had an IGA of 1, all others had an IGA of 0. The mean age was 59.5 years, 79.4% were women, and the mean PP-NRS was 0.7.
The results for the primary endpoint of time from baseline to relapse showed that participants with nemolizumab withdrawal had a median time to relapse of 112.5 days, while the time to relapse in those on continuous treatment was undetermined until week 24 because the event rate was too low. “The hazard ratio of relapse was 0.125, which means that it was 8 times more likely to relapse in the nemolizumab withdrawal arm than in the nemolizumab continuous arm,” Prof. Legat specified. In the withdrawal arm, 12 out of 16 participants (75%) relapsed, compared with 3 out of 18 (16.7%) continuing nemolizumab. The safety data showed a profile that was in line with previous data.
“These findings support the continued use of nemolizumab beyond 52 weeks of treatment among patients who are clinical responders,” Prof Legat concluded.
- Legat F. Durability of response to nemolizumab in patients with moderate-to-severe prurigo nodularis: Results from a randomised placebo-controlled withdrawal phase 3b study. D1T01.1A, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support was provided by Karin Drooff, MPH
Posted on
Previous Article
« Atopic dermatitis early in life imposes a lifelong psychosocial burden Next Article
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis »
« Atopic dermatitis early in life imposes a lifelong psychosocial burden Next Article
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
August 2, 2021
Hair shedding related to COVID-19 doesn’t last long
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com